S. 3788: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act

This bill, titled the Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act, aims to enhance the transparency of drug labeling requirements. It proposes several amendments to existing regulations concerning how drugs are labeled, particularly regarding the disclosure of manufacturing and supply chain information. Here’s a summary of its main features:

Key Provisions of the Bill

• Enhanced Drug Labeling Requirements: The bill mandates that all drug labels include detailed information about the manufacturer, packer, or distributor. Specifically, the label must contain the name, place of business, and a unique facility identifier. Alternatively, it could provide a link, barcode, QR code, or other means to access an electronic portal with this information.
• Active Pharmaceutical Ingredients (APIs): For drugs that contain active pharmaceutical ingredients, the bill requires that the label must include information about the original manufacturer of each API, the manufacturer of the finished product, and the packer or distributor, if any. This information must similarly be accessible via the electronic portal or through traditional paper formats if requested by consumers.
• Exemptions from Customs Regulations: The bill includes a specific exemption from certain customs marking requirements for those finished drug products that already comply with the new labeling requirements set forth in the Federal Food, Drug, and Cosmetic Act.
• Implementation by the Secretary: The Secretary of Health and Human Services will be responsible for issuing regulations to implement these new labeling requirements. These regulations will allow for some flexibility and alternatives in how the requirements are applied, including the use of electronic means for displaying the required information. The regulations will become effective no sooner than one year after publication.
• Accessibility of Information: Manufacturers, packers, or distributors are required to make the labeling information available electronically as well as provide it in paper form upon request. This is intended to ensure that consumers have easy access to crucial information about the drugs they are using.

Definitions

The bill also defines the term “original manufacturer” as the last establishment that conducts substantial manufacturing activities before the drug is introduced into interstate commerce. This definition helps clarify which entities are responsible for providing the necessary labeling information.

Conclusion of Provisions

The overall goal of this legislation is to improve the transparency and accountability of pharmaceutical products in the market, thereby helping consumers make more informed choices about the medications they use.

Relevant Companies

• PFE (Pfizer Inc.) - As a leading pharmaceutical manufacturer, Pfizer would likely need to adjust its labeling practices to comply with the new requirements regarding the disclosure of manufacturing sources and details about its products.
• MRK (Merck & Co., Inc.) - Merck will be impacted regarding the requirement to disclose additional facility information for both its finished products and active ingredients sourced from various manufacturers.
• ABBV (AbbVie Inc.) - AbbVie may have to adapt its product labels to adhere to the new transparency guidelines, especially concerning the identification of original manufacturers of its drugs.